AER-901, an inhaled formulation of imatinib being developed as a treatment for pulmonary arterial hypertension (PAH), has been granted…
Articles by Steve Bryson, PhD
Routine blood screenings and non-invasive clinical tests may predict disease severity and mortality in people with pulmonary hypertension (PH),…
The PAPi blood pressure test was able to accurately predict mortality in Asian people with pulmonary arterial hypertension (PAH),…
The likelihood of developing pulmonary hypertension (PH) is low among people in southern Italy, suggests a study that draws from…
The U.S. Food and Drug Administration (FDA) has accepted an updated application asking that the dry-powder inhalation therapy…
Altavant Sciences has opened ELEVATE 2, its global Phase 2b clinical trial into the safety…
Iron replacement did not affect disease severity or the ability to function in people with…
Diminazene aceturate (DIZE), an approved antiparasitic medication, lessened the development of pulmonary arterial hypertension…
Adipose (fat) tissue may contribute to the development of pulmonary arterial hypertension (PAH)…
A gene called DNMT3BÂ was found for the first time to be a mediator of blood vessel…
Elevated blood levels of the kidney disease biomarker creatinine and the heart failure biomarker NT-proBNP were found to…
People with both pulmonary hypertension (PH) and interstitial lung disease (ILD) have worse survival outcomes than ILD patients who…